Corbus Pharmaceuticals Holdings Inc CRBP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
-
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
-
Corbus Pharma Reports Positive Top-Line Data From Weight-Loss Drug Study
-
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
-
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
-
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
-
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
Trading Information
- Previous Close Price
- $4.22
- Day Range
- $3.90–4.23
- 52-Week Range
- $3.87–12.88
- Bid/Ask
- $3.87 / $3.97
- Shares Outstanding
- 19.34M
- Market Cap
- $75.72M
- Volume/Avg
- 673,247 / 910,770
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 36
- Website
- https://www.corbuspharma.com
Valuation
|
Metric
|
CRBP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.77 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CRBP
|
|---|---|
Quick Ratio | 5.49 |
Current Ratio | 5.71 |
Interest Coverage | — |
Quick Ratio
CRBP
Profitability
|
Metric
|
CRBP
|
|---|---|
Return on Assets (Normalized) | −70.57% |
Return on Equity (Normalized) | −82.15% |
Return on Invested Capital (Normalized) | −84.86% |
Return on Assets
CRBP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|GG%Ml% | LOCK|^mxH | $142B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|cv?s^N | LOCK|#yl> | $96B | |||
| Moderna Inc
MRNA
| LOCK|rCg^jpH | LOCK|>#! | $89B | |||
| argenx SE ADR
ARGX
| LOCK|nwq@Dz@ | LOCK|?d | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|wDp%G?T | LOCK|T>$ | $43B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|##dzl<z< | LOCK|^#G&H | $30B | |||
| Incyte Corp
INCY
| LOCK|%?^ch$ | LOCK|y& | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|T&R<%>? | LOCK|BD# | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|m!&c>Q | LOCK|V&JY | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|@hLlX$ | LOCK|Z@$ | $15B |
United States